<DOC>
	<DOCNO>NCT03083184</DOCNO>
	<brief_summary>The purpose study assess efficacy combine solution ethanol ( 4 % ) low molecular weight heparin LMWH prevent tunnelled dialysis catheter infection chronic hemodialysis patient</brief_summary>
	<brief_title>Evaluation Efficacy inTerdialytic `` Ethanol 40 % v/v - enoxapaRin 1000 U/mL '' Lock solutioN Prevent Tunnelled Catheter Infections Chronic Hemodialysis Patients</brief_title>
	<detailed_description>In France , central venous catheter use 20 30 % chronic hemodialysis patient vascular access device . In patient population recommend device tunnel dialysis catheter ( TC ) . TC-related infection ( TCI ) TC dysfunction two major complication associate increase antibiotic consumption , hospital stay , health cost mortality . Strategies prevent TCI target endoluminal biofilm formation , major cause long-term catheter colonization . Unfractionated heparin ( UFH ) , 5000 U/mL , standard interdialytic lock solution prevention TC thrombosis . A lower-UFH concentration ( 1000U/mL ) associate similar catheter patency . However , UFH antibiofilm property . Antibiotic lock decrease rate TCI include TC- related bloodstream infection ( TCBSI ) exit-site infection ( ESI ) . The widespread use antibiotic lock solution raise concern , however , side effect risk development antimicrobial-resistant microorganism . Ethanol inexpensive antiseptic agent activity broad range bacteria fungi commonly involve TCI . It act non-specific protein denaturation thus less likely promote antimicrobial resistance . Ethanol concentration 40 % v/v highly effective eradicate biofilm significant impact integrity silicone polyurethane TCs mechanical property . A small randomized control trial perform chronic hemodialysis patient TC suggest once-weekly instillation interdialytic ethanol lock effective preventing TCBSI . However , ethanol anticoagulant property may induce TC dysfunction use alone . Experimental data provide evidence combine solution ethanol injectable anticoagulant promising lock solution prevent TC infection dysfunction . UFH , whatever concentration , mixed ethanol 40 % v/v precipitation . ERA-EDTA recommends use low molecular weight heparin ( LMWHs ) blood circuit anticoagulation dialysis session . Like UFH , LMWHs antibiofilm property . In contrast , LMWHs mix ethanol 40 % v/v enoxaparin high solubility , 1300 U/mL . Our group demonstrate ethanol 40 % v/v - enoxaparin 400 U/mL stable , compatible TC material exhibit antibiofilm anticoagulant property vitro ( patent ) . No clinical study previously assess efficacy combine solution ethanol LMWH prevent TCI chronic hemodialysis patient . Screening Patients eligible participate study identify clinical research assistant study centre begin study weekly . Data record medical record use . Enrolment Eligible patient , previously identify screening procedure , recruit routine hemodialysis session investigator centre participate study Randomization Enrolled patient randomly assign 1:1 ratio either intervention group ( Ethenox ) control group ( reference solution : UFH 5000 U/mL citrate 4 % w/v depend solution generally use ) . Random allocation perform minimization use computer algorithm . Minimization stratum study centre , incident prevalent nature TC prevalent group existence previous infection TC place . Single blind procedure The study perform single blind patient analyst . The recognisable smell ethanol need prepare Ethenox lock solution rule blind healthcare staff . Treatment Study treatment ( Ethenox intervention group reference solution control group : UFH 5000 U/mL citrate 4 % w/v accord usual practice ) use hemodialysis nurse TC lock solution hemodialysis session successive TCs use study . All centre participate study use similar hygiene protocol TC placement maintenance accordance guideline draw Haute Autorité de Santé Société Française d'Hygiène Hospitalière . Audits conduct study ensure compliance guideline . Study assessments Bacteriological sampling perform accordance guideline TCI . A monthly blood sample take part routine care give patient . Data collect weekly electronic case report form ( e-CRF ) except endpoint data adjudication serious adverse event , record continuously .</detailed_description>
	<mesh_term>Infection</mesh_term>
	<mesh_term>Communicable Diseases</mesh_term>
	<mesh_term>Pharmaceutical Solutions</mesh_term>
	<mesh_term>Ethanol</mesh_term>
	<criteria>endstage renal disease chronic hemodialysis/hemodiafiltration least three time week functional TC insert least two week Social security cover Written inform consent</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2017</verification_date>
	<keyword>Hemodialysis</keyword>
	<keyword>hemodiafiltration</keyword>
	<keyword>tunnel dialysis catheter</keyword>
	<keyword>interdialytic lock solution</keyword>
	<keyword>prevent tunnel catheter infection</keyword>
</DOC>